211 related articles for article (PubMed ID: 33646304)
41. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Miesbach W; Meijer K; Coppens M; Kampmann P; Klamroth R; Schutgens R; Tangelder M; Castaman G; Schwäble J; Bonig H; Seifried E; Cattaneo F; Meyer C; Leebeek FWG
Blood; 2018 Mar; 131(9):1022-1031. PubMed ID: 29246900
[TBL] [Abstract][Full Text] [Related]
42. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice.
Wu YM; Kao CY; Huang YJ; Yu IS; Lee HS; Lai HS; Lee PH; Lin CN; Lin SW
Cell Transplant; 2010; 19(9):1169-80. PubMed ID: 20412633
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
[TBL] [Abstract][Full Text] [Related]
44. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
Markusic DM; Hoffman BE; Perrin GQ; Nayak S; Wang X; LoDuca PA; High KA; Herzog RW
EMBO Mol Med; 2013 Nov; 5(11):1698-709. PubMed ID: 24106230
[TBL] [Abstract][Full Text] [Related]
45. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
[TBL] [Abstract][Full Text] [Related]
46. Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.
Wang X; Moghimi B; Zolotukhin I; Morel LM; Cao O; Herzog RW
Mol Ther; 2014 Jun; 22(6):1139-1150. PubMed ID: 24609143
[TBL] [Abstract][Full Text] [Related]
47. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
48. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
49. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model.
French RA; Samelson-Jones BJ; Niemeyer GP; Lothrop CD; Merricks EP; Nichols TC; Arruda VR
Blood Adv; 2018 Mar; 2(5):505-508. PubMed ID: 29500218
[TBL] [Abstract][Full Text] [Related]
50. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
[TBL] [Abstract][Full Text] [Related]
51. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
[TBL] [Abstract][Full Text] [Related]
52. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.
Mingozzi F; Chen Y; Murphy SL; Edmonson SC; Tai A; Price SD; Metzger ME; Zhou S; Wright JF; Donahue RE; Dunbar CE; High KA
Mol Ther; 2012 Jul; 20(7):1410-6. PubMed ID: 22565846
[TBL] [Abstract][Full Text] [Related]
54. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
55. The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.
Shi Q; Mattson JG; Fahs SA; Geurts AM; Weiler H; Montgomery RR
Blood Adv; 2020 Jan; 4(1):55-65. PubMed ID: 31899798
[TBL] [Abstract][Full Text] [Related]
56. Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent.
Kelly ME; Zhuo J; Bharadwaj AS; Chao H
Mol Ther; 2009 May; 17(5):857-63. PubMed ID: 19240690
[TBL] [Abstract][Full Text] [Related]
57. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
58. A Preconditioning Strategy to Augment Retention and Engraftment Rate of Donor Cells During Hepatocyte Transplantation.
Hsu YC; Yu IS; Tsai YF; Wu YM; Chen YT; Sheu JC; Lin SW
Transplantation; 2021 Apr; 105(4):785-795. PubMed ID: 32976366
[TBL] [Abstract][Full Text] [Related]
59. Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.
Lytle AM; Brown HC; Paik NY; Knight KA; Wright JF; Spencer HT; Doering CB
Mol Ther Methods Clin Dev; 2016; 3():15056. PubMed ID: 26909355
[TBL] [Abstract][Full Text] [Related]
60. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
